Guardian Pharmacy Services (GRDN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
26 Mar, 2026Executive summary
Annual meeting scheduled for May 5, 2026, to elect two Class II directors, approve executive compensation, determine frequency of say-on-pay votes, and ratify Ernst & Young LLP as auditor.
Only holders of record as of March 13, 2026, may vote; quorum requires majority of outstanding shares.
Board recommends voting for all proposals and for annual say-on-pay votes.
Voting matters and shareholder proposals
Proposals include election of two Class II directors, advisory approval of executive compensation, advisory vote on frequency of say-on-pay (Board recommends annual), and ratification of Ernst & Young LLP as auditor.
Shareholders may submit proposals for the 2027 meeting by November 26, 2026.
Board of directors and corporate governance
Board consists of eight directors, with a classified structure (three classes).
Recent changes include loss of controlled company status and transition to majority independent board.
Three standing committees: Audit, Compensation, and Nominating and Governance, all with independent members.
Stockholders' Agreement previously granted certain nomination rights, some of which have expired due to share sales.
Board leadership structure separates Chairman and CEO roles.
Latest events from Guardian Pharmacy Services
- Expanding assisted living pharmacy services through tech, analytics, and strategic acquisitions.GRDN
Stephens Annual Investment Conference8 Jul 2026 - Strong 2024 growth and expansion, with 2025 outlook positive despite IPO-related net loss.GRDN
Q4 20248 Jul 2026 - Tech-enabled growth and legislative advocacy position the company for continued market expansion.GRDN
Stephens 26th Annual Investment Conference | NASH20248 Jul 2026 - Strong growth, stable margins, and expanding market share position the company for continued success.GRDN
Raymond James & Associates’ 46th Annual Institutional Investors Conference30 Jun 2026 - Strong quarter, raised guidance, and poised for growth in the fragmented assisted living pharmacy market.GRDN
Bank of America Global Healthcare Conference 202613 May 2026 - 13% ALF market share, $1.45B revenue, and tech-driven growth deliver strong outcomes.GRDN
Investor presentation11 May 2026 - Q1 2026 revenue and net income rose, prompting higher full-year EBITDA guidance.GRDN
Q1 20266 May 2026 - Capturing 13% of the ALF pharmacy market, growth is driven by tech, service, and disciplined expansion.GRDN
44th Annual J.P. Morgan Healthcare Conference12 Apr 2026 - Annual meeting to vote on directors, executive pay, say-on-pay frequency, and auditor ratification.GRDN
Proxy filing26 Mar 2026